{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:50:35Z","timestamp":1788285035794,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01220"],"award-info":[{"award-number":["PI19\/01220"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015528","name":"Universidad de la Laguna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015528","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) causes about 10% of cases of end stage renal disease. Disease progression rate\u00a0is heterogeneous. Tolvaptan is presently\u00a0the only specific therapeutic option to slow kidney function decline in adults at risk of rapidly progressing ADPKD with chronic kidney disease (CKD) stages 1\u20134. Thus, a reliable evaluation of kidney function in patients with ADPKD is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the agreement between measured (mGFR) and estimated glomerular filtration rate (eGFR) by 61 formulas based on creatinine and\/or cystatin-C (eGFR) in 226 ADPKD patients with diverse GFR values, from predialysis to glomerular hyperfiltration. Also, we evaluated whether incorrect categorization of CKD using eGFR may interfere with the indication and\/or reimbursement of Tolvaptan treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No formula showed acceptable agreement with mGFR. Total Deviation Index averaged about 50% for eGFR based on creatinine and\/or cystatin-C, indicating that 90% of the estimations of GFR showed bounds of error of 50% when compared with mGFR. In 1 out of 4 cases with mGFR\u2009&lt;\u200930\u00a0ml\/min, eGFR provided estimations above this threshold. Also, in half of the cases with mGFR between 30 and 40\u00a0ml\/min, formulas estimated values\u2009&lt;\u200930\u00a0ml\/min.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The evaluation of renal function with formulas in ADPKD patients is unreliable. Extreme deviation from real renal function is quite frequent. The consequences of this error deserve attention, especially in rapid progressors who may benefit from starting treatment with tolvaptan and in whom specific GFR thresholds are needed for the indication or reimbursement. Whenever possible, mGFR is recommended.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-022-01286-0","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T06:03:51Z","timestamp":1648706631000},"page":"2109-2118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method"],"prefix":"10.1093","volume":"35","author":[{"given":"Rosa Miquel","family":"Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Luis-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Vanesa P\u00e9rez","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Gonz\u00e1lez","family":"Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Delgado-Mall\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Escamilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Oramas","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Estupi\u00f1\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coriolano Cruz","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia Negr\u00edn","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura D\u00edaz","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Pitti","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Hern\u00e1ndez","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Gonz\u00e1lez-Rinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Gonz\u00e1lez-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Ferrer-Moure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a L\u00f3pez-Botet","family":"Zulueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Carlos","family":"Rodriguez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Gaspari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Porrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"1286_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1471-2369-14-186","volume":"14","author":"V Mart\u00ednez","year":"2013","unstructured":"Mart\u00ednez V, Comas J, Arcos E, D\u00edaz JM, Muray S, Cabezuelo J, Ballar\u00edn J, Ars E, Torra R (2013) Renal replacement therapy in ADPKD patients: a 25-year survey based on the Catalan registry. BMC Nephrol 14:186. https:\/\/doi.org\/10.1186\/1471-2369-14-186","journal-title":"BMC Nephrol"},{"key":"1286_CR2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","volume":"67","author":"FT Chebib","year":"2016","unstructured":"Chebib FT, Torres VE (2016) Autosomal dominant polycystic kidney disease: core curriculum. Am J Kidney Dis 67:792\u2013810. https:\/\/doi.org\/10.1053\/j.ajkd.2015.07.037","journal-title":"Am J Kidney Dis"},{"key":"1286_CR3","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S01406736(18)32782-X","volume":"393","author":"E Cornec-Le Gall","year":"2019","unstructured":"Cornec-Le Gall E, Alam A, Perrone RD (2019) Autosomal dominant polycystic kidney disease. Lancet 393:919\u2013935. https:\/\/doi.org\/10.1016\/S01406736(18)32782-X","journal-title":"Lancet"},{"key":"1286_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","volume":"4","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE (2018) Polycystic kidney disease. Nat Rev Dis Primers 4:50. https:\/\/doi.org\/10.1038\/s41572-018-0047-y","journal-title":"Nat Rev Dis Primers"},{"key":"1286_CR5","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ (2008) Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 359:1477\u20131485. https:\/\/doi.org\/10.1056\/NEJMcp0804458","journal-title":"N Engl J Med"},{"key":"1286_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall E, Marie-Pierre Audr\u00e9zet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C et al (2016) The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney. J Am Soc Nephrol 27:942\u2013951. https:\/\/doi.org\/10.1681\/ASN.2015010016","journal-title":"J Am Soc Nephrol"},{"key":"1286_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41581-018-0080-9","volume":"15","author":"E Porrini","year":"2019","unstructured":"Porrini E, Ruggenenti P, Luis-Lima S, Carrara F, Jim\u00e9nez A, de Vries APJ et al (2019) Estimated GFR: time for a critical appraisal. Nat Rev Nephrol 15:177\u2013190. https:\/\/doi.org\/10.1038\/s41581-018-0080-9","journal-title":"Nat Rev Nephrol"},{"key":"1286_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ndt\/gfx043","volume":"33","author":"VE Torres","year":"2018","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A et al (2018) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial for the TEMPO 4:4 trial investigators. Nephrol Dial Transplant 33:477\u2013489. https:\/\/doi.org\/10.1093\/ndt\/gfx043","journal-title":"Nephrol Dial Transplant"},{"key":"1286_CR9","unstructured":"https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-tolvaptan-Jinarc-PQRAD.pdf?x42633; accessed 02 Dec 2021"},{"key":"1286_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","volume":"31","author":"RT Gansevoort","year":"2016","unstructured":"Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A et al (2016) Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European Renal Best Practice. Nephrol Dial Transplant 31:337\u2013348. https:\/\/doi.org\/10.1093\/ndt\/gfv456","journal-title":"Nephrol Dial Transplant"},{"key":"1286_CR11","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1093\/ndt\/gfx323","volume":"33","author":"S Luis-Lima","year":"2018","unstructured":"Luis-Lima S, Gaspari F, Negr\u00edn-Mena N, Carrara F, D\u00edaz-Mart\u00edn L, Jim\u00e9nez-Sosa A et al (2018) Iohexol plasma clearance simplified by dried blood spot testing. Nephrol Dial Transplant 33:1597\u20131603. https:\/\/doi.org\/10.1093\/ndt\/gfx323","journal-title":"Nephrol Dial Transplant"},{"key":"1286_CR12","unstructured":"https:\/\/lfr.ecihucan.es\/en\/renal-function-lab; accessed 02 Dec 2021"},{"key":"1286_CR13","first-page":"955","volume":"104","author":"E Krutz\u00e9n","year":"1984","unstructured":"Krutz\u00e9n E, B\u00e4ck SE, Nilsson-Ehle I, Nilsson-Ehle P (1984) Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate. J Lab Clin Med 104:955\u2013961","journal-title":"J Lab Clin Med"},{"key":"1286_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000491022","volume":"48","author":"R Magistronia","year":"2018","unstructured":"Magistronia R, Corsib C, Mart\u00ed T, Torra R (2018) A review of the imaging techniques for measuring kidney and cyst volume in establishing autosomal dominant polycystic kidney disease progression. Am J Nephrol 48:67\u201378. https:\/\/doi.org\/10.1159\/000491022","journal-title":"Am J Nephrol"},{"key":"1286_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ki.2015.71","volume":"88","author":"H Bhutani","year":"2015","unstructured":"Bhutani H, Smith V, Rahbari-Oskoui F, Mittal A, Grantham JJ, Torres VE et al (2015) A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int 88:146\u2013151. https:\/\/doi.org\/10.1038\/ki.2015.71","journal-title":"Kidney Int"},{"key":"1286_CR16","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41366-019-0476-z","volume":"44","author":"M L\u00f3pez-Mart\u00ednez","year":"2020","unstructured":"L\u00f3pez-Mart\u00ednez M, Luis-Lima S, Morales E, Navarro-D\u00edaz M, Negr\u00edn-Mena N, Folgueras T et al (2020) The estimation of GFR and the adjustment for BSA in overweight and obesity: a dreadful combination of two errors. Int J Obes (Lond) 44:1129\u20131140. https:\/\/doi.org\/10.1038\/s41366-019-0476-z","journal-title":"Int J Obes (Lond)"},{"key":"1286_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-0562-7","volume-title":"Statistical tools for measuring agreement","author":"L Lin","year":"2012","unstructured":"Lin L, Hedayat AS, Wu W (2012) Statistical tools for measuring agreement. Springer, New York"},{"key":"1286_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ki.2013.47","volume":"84","author":"F Gaspari","year":"2013","unstructured":"Gaspari F, Ruggenenti P, Porrini E, Motterlini N, Cannata A, Carrara F et al (2013) The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 84:164\u2013173. https:\/\/doi.org\/10.1038\/ki.2013.47","journal-title":"Kidney Int"},{"key":"1286_CR19","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","volume":"65","author":"EL Knight","year":"2004","unstructured":"Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC et al (2004) Factors influencing serum cystatin-C levels other than renal function and the impact on renal function measurement. Kidney Int 65:1416\u20131421. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00517.x","journal-title":"Kidney Int"},{"key":"1286_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/ki.2008.638","volume":"75","author":"LA Stevens","year":"2009","unstructured":"Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM et al (2009) Factors other than glomerular filtration rate affect serum cystatin-C levels. Kidney Int 75:652\u2013660. https:\/\/doi.org\/10.1038\/ki.2008.638","journal-title":"Kidney Int"},{"key":"1286_CR21","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1093\/ndt\/gfs561","volume":"28","author":"AT Reutens","year":"2013","unstructured":"Reutens AT, Bonnet F, Lantieri O, Roussel R, Balkau B, Epidemiological Study on the Insulin Resistance Syndrome Study Group (2013) Epidemiological study on the insulin resistance syndrome study group. The association between cystatin-C and incident type 2 diabetes is related to central adiposity. Nephrol Dial Transplant 28:1820\u20131829. https:\/\/doi.org\/10.1093\/ndt\/gfs561","journal-title":"Nephrol Dial Transplant"},{"key":"1286_CR22","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/oby.2009.96","volume":"17","author":"N Naour","year":"2009","unstructured":"Naour N, Fellahi S, Renucci JF, Poitou C, Rouault C, Basdevantet A et al (2009) Potential contribution of adipose tissue to elevated serum cystatin-C in human obesity. Obesity (Silver Spring) 17:2121\u20132126. https:\/\/doi.org\/10.1038\/oby.2009.96","journal-title":"Obesity (Silver Spring)"},{"key":"1286_CR23","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","volume":"37","author":"GM Reaven","year":"1988","unstructured":"Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595\u20131607. https:\/\/doi.org\/10.2337\/diab.37.12.1595","journal-title":"Diabetes"},{"key":"1286_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ndt\/gfy086","volume":"34","author":"S Luis-Lima","year":"2019","unstructured":"Luis-Lima S, Escamilla-Cabrera B, Negr\u00edn-Mena N, Estupi\u00f1\u00e1n S, Delgado-Mall\u00e9n P, Marrero-Miranda D et al (2019) Chronic kidney disease staging with cystatin C or creatinine-based formulas: flipping the coin. Nephrol Dial Transplant 34:287\u2013294. https:\/\/doi.org\/10.1093\/ndt\/gfy086","journal-title":"Nephrol Dial Transplant"},{"key":"1286_CR25","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jinarc-epar-product-information_en.pdf; accessed 02 Dec 2021"},{"key":"1286_CR26","unstructured":"https:\/\/senefro.org\/contents\/webstructure\/APKD\/Guias_Sociedad_Otsuka_V03.pdf; accessed 02 Dec 2021"},{"key":"1286_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000256657","volume":"31","author":"B Orskov","year":"2010","unstructured":"Orskov B, Borresen ML, Feldt-Rasmussen B, \u00d8stergaard O, Laursen I, Strandgaard S et al (2010) Estimating glomerular filtration rate using the new CKD-EPI equation and other equations in patients with autosomal dominant polycystic kidney disease. Am J Nephrol 31:53\u201357. https:\/\/doi.org\/10.1159\/000256657","journal-title":"Am J Nephrol"},{"key":"1286_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1053\/j.ajkd.2013.03.030","volume":"62","author":"EM Spithoven","year":"2013","unstructured":"Spithoven EM, Meijer E, Boertien WE, Sinkeler SJ, Tent H, de Jong PE et al (2013) Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations. Am J Kidney Dis 62:531\u2013540. https:\/\/doi.org\/10.1053\/j.ajkd.2013.03.030","journal-title":"Am J Kidney Dis"},{"key":"1286_CR29","doi-asserted-by":"publisher","first-page":"e32533","DOI":"10.1371\/journal.pone.0032533","volume":"7","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, Gaspari F, Cannata A, Carrara F, Cella C, Ferrari S et al (2012) GFR-ADPKD Study Group. Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study. PLoS One 7:e32533. https:\/\/doi.org\/10.1371\/journal.pone.0032533","journal-title":"PLoS One"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01286-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-022-01286-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01286-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:44Z","timestamp":1777564544000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/35\/8\/2109\/8326024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1007\/s40620-022-01286-0","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jose Carlos Rodriguez P\u00e9rez sure name update","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of HUC-Tenerife, HUDN-Gran Canaria and FJD-Madrid. Study procedures were performed according to the principles of the Declaration of Helsinki and written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}